| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARK2 |
| Uniprot No | O60260 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-465aa |
| 氨基酸序列 | MIVFVRFNSSHGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQEMNATGGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPPAGSPAGRSIYNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHCPGTSAEFFFKCGAHPTSDKETSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDRQFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEGECSAVFEASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV |
| 预测分子量 | 55.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PARK2(Parkin)重组蛋白的3篇代表性文献及其摘要概括：
1. **《Mechanisms of PINK1-dependent ubiquitin phosphorylation and Parkin activation》**
- 作者：Kazuhiro Iwai 等
- 摘要：该研究利用重组Parkin蛋白和PINK1激酶，揭示了PINK1通过磷酸化泛素和Parkin自身激活Parkin的分子机制，阐明了其在线粒体自噬中的关键调控作用。
2. **《Structure of Parkin reveals mechanisms for ubiquitin ligase activation》**
- 作者：Andrew J. Whitworth 等
- 摘要：通过解析重组人源Parkin蛋白的晶体结构，发现了其自抑制构象及磷酸化诱导的激活机制，为帕金森病相关突变导致的功能丧失提供了结构基础。
3. **《Reconstitution of the Parkinson’s disease-associated protein Parkin in vitro》**
- 作者：R. J. Youle 团队
- 摘要：研究利用大肠杆菌表达系统纯化重组Parkin蛋白，建立了体外泛素化实验体系，证明Parkin在PINK1调控下可介导线粒体蛋白的多泛素化修饰，推动损伤线粒体清除。
注：以上文献为示例性质，实际引用需核对具体论文标题及作者信息。近年研究多聚焦于Parkin与PINK1协同作用的结构与功能机制，建议通过PubMed或Google Scholar以“recombinant PARK2/Parkin”为关键词检索最新文献。
**Background of PARK2 Recombinant Protein**
The PARK2 gene, located on chromosome 6 (6q26), encodes parkin, a key E3 ubiquitin ligase involved in the ubiquitin-proteasome system (UPS). Discovered in 1998. PARK2 mutations are linked to autosomal recessive juvenile Parkinsonism (AR-JP), a form of early-onset Parkinson’s disease (PD). Parkin plays a critical role in mitophagy, protein quality control, and mitochondrial homeostasis by tagging damaged or misfolded proteins with ubiquitin molecules for proteasomal degradation. Loss-of-function mutations disrupt these processes, leading to neuronal accumulation of toxic substrates and neurodegeneration.
Recombinant PARK2 protein is engineered *in vitro* using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional parkin for research. Its production enables mechanistic studies of parkin’s structure, enzymatic activity, and interactions with substrates like ubiquitin, PINK1. and mitochondrial proteins. Researchers utilize PARK2 recombinant protein to model PD pathogenesis, screen therapeutic compounds, or develop gene therapies targeting parkin dysfunction.
Studies highlight its role in mitigating oxidative stress, regulating synaptic vesicle trafficking, and modulating inflammatory responses, underscoring its broader relevance beyond PD. However, challenges remain in mimicking post-translational modifications (e.g., phosphorylation by PINK1) critical for parkin activation. Advances in recombinant technology continue to refine parkin production, aiding drug discovery and understanding neurodegenerative pathways.
×
